Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Reata Pharma (RETA)

Reata Pharma (RETA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,131,436
  • Shares Outstanding, K 36,404
  • Annual Sales, $ 11,490 K
  • Annual Income, $ -297,390 K
  • 60-Month Beta 1.24
  • Price/Sales 105.51
  • Price/Cash Flow N/A
  • Price/Book 9.49
Trade RETA with:

Options Overview Details

View History
  • Implied Volatility 87.33% ( -6.29%)
  • Historical Volatility 76.17%
  • IV Percentile 51%
  • IV Rank 15.85%
  • IV High 279.74% on 12/01/21
  • IV Low 51.10% on 06/25/21
  • Put/Call Vol Ratio 0.88
  • Today's Volume 126
  • Volume Avg (30-Day) 355
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 7,359
  • Open Int (30-Day) 15,177

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -1.90
  • Number of Estimates 2
  • High Estimate -1.78
  • Low Estimate -2.02
  • Prior Year -2.00
  • Growth Rate Est. (year over year) +5.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.84 +20.28%
on 05/25/22
36.31 -14.40%
on 06/08/22
+3.99 (+14.73%)
since 05/24/22
3-Month
20.24 +53.60%
on 05/09/22
37.58 -17.30%
on 03/25/22
-5.67 (-15.43%)
since 03/24/22
52-Week
20.24 +53.60%
on 05/09/22
153.41 -79.74%
on 06/29/21
-111.27 (-78.17%)
since 06/24/21

Most Recent Stories

More News
Why Is Reata Pharmaceuticals, Inc. (RETA) Up 53.1% Since Last Earnings Report?

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

RETA : 31.08 (-6.67%)
PBYI : 2.85 (-1.72%)
Reata (RETA) Up More Than 12% YTD: What's Driving the Rally?

Reata's (RETA) prospects are likely to improve following the potential approval of its lead candidate, omaveloxolone, expected by the end of 2022 is likely driving its share price.

ALKS : 29.71 (+0.51%)
RETA : 31.08 (-6.67%)
PRPH : 11.73 (+1.65%)
SESN : 0.8177 (-0.85%)
Reata (RETA) Friedreich's Ataxia NDA Gets Priority Review

Reata (RETA) is seeking approval for omaveloxolone as a treatment for neuromuscular disorder Friedreich's ataxia. The FDA grants priority review to the NDA for the same. Stock rises.

ALKS : 29.71 (+0.51%)
RETA : 31.08 (-6.67%)
PRPH : 11.73 (+1.65%)
SESN : 0.8177 (-0.85%)
Reata Pharmaceuticals Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration...

RETA : 31.08 (-6.67%)
Reata (RETA) Q1 Earnings Top, Omaveloxolone MAA Likely in Q4

Reata (RETA) reports a narrower-than-expected loss for the first quarter of 2022 while revenues miss estimates.

ABBV : 152.34 (+1.93%)
RETA : 31.08 (-6.67%)
LYEL : 6.66 (-2.06%)
ELYM : 3.65 (-6.17%)
Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Misses Revenue Estimates

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 10.18% and 52.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

RETA : 31.08 (-6.67%)
TRVN : 0.4181 (-9.11%)
Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced financial results for the first...

RETA : 31.08 (-6.67%)
Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More

Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.

EXEL : 22.22 (+4.17%)
CPRX : 6.64 (-0.75%)
EPZM : 0.9540 (-0.31%)
RETA : 31.08 (-6.67%)
BHC : 8.75 (+20.36%)
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -90.32% and 89.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

MRSN : 5.00 (+1.83%)
RETA : 31.08 (-6.67%)
Reata Pharmaceuticals, Inc. to Report First Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on May 10, 2022

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial...

RETA : 31.08 (-6.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Reata Pharmaceuticals is a clinical-stage pharmaceutical company primarily focused on discovering, developing and commercializing small-molecule based innovative therapies for treating severe, life-threatening diseases with a few or no approved therapies. The company is developing its lead pipeline candidates...

See More

Key Turning Points

3rd Resistance Point 36.25
2nd Resistance Point 35.13
1st Resistance Point 33.10
Last Price 31.08
1st Support Level 29.95
2nd Support Level 28.83
3rd Support Level 26.80

See More

52-Week High 153.41
Fibonacci 61.8% 102.54
Fibonacci 50% 86.82
Fibonacci 38.2% 71.11
Last Price 31.08
52-Week Low 20.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar